Unresectable Or Metastatic Non Squamous Non Small Cell Lung Cancer Nsclc Whose Tumors Have Her2 Erbb2 Tyrosine Kinase Domain Activating Mutations — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for unresectable or metastatic non squamous non small cell lung cancer nsclc whose tumors have her2 erbb2 tyrosine kinase domain activating mutations. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

Originators in Unresectable Or Metastatic Non Squamous Non Small Cell Lung Cancer Nsclc Whose Tumors Have Her2 Erbb2 Tyrosine Kinase Domain Activating Mutations

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating unresectable or metastatic non squamous non small cell lung cancer nsclc whose tumors have her2 erbb2 tyrosine kinase domain activating mutations. Each bar = one year. Y-axis scaled to peak year (1 patents).

Approved drugs ranked by patent estate

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Related

• Unresectable Or Metastatic Non Squamous Non Small Cell Lung Cancer Nsclc Whose Tumors Have Her2 Erbb2 Tyrosine Kinase Domain Activating Mutations — full disease profile
• AI Patent Landscape Report — type "unresectable or metastatic non squamous non small cell lung cancer nsclc whose tumors have her2 erbb2 tyrosine kinase domain activating mutations" for an AI exec memo
• Company Patent Rankings
• Biosimilar Opportunity Scanner